Multidrug-resistant Tuberculosis
📧 Sign up to get email alerts when something new happens for Multidrug-resistant Tuberculosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2015-12-02Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis [Phase 3]
A Phase 3 trial evaluating TMC207 (bedaquiline) for pulmonary multidrug-resistant tuberculosis has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2015-07-14Clinical Trial Update: Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in Uzbekistan
Clinical trial update on the effectiveness of a simplified short regimen for multidrug-resistant tuberculosis in Uzbekistan. The trial is sp…
-
FDA approval · 2015-05-14FDA Approved: SIRTURO — Supplemental Application (Janssen Products, LP)
FDA approved a supplemental application for SIRTURO (bedaquiline fumarate) filed by Janssen Products, LP.
-
FDA approval · 2014-10-17FDA Approved: SIRTURO — Supplemental Application (Janssen Products, LP)
FDA approved a supplemental application for SIRTURO (bedaquiline fumarate) submitted by Janssen Products, LP. The action completes an additi…
-
FDA approval · 2014-08-04FDA Approved: SIRTURO — Supplemental Application (Janssen Products, LP)
FDA approved a supplemental application for SIRTURO (bedaquiline fumarate) from Janssen Products, LP, likely updating the labeling or expand…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2014-06-23Clinical Trial Update: Global Consortium for Drug-resistant Tuberculosis Diagnostics
The document reports that the Global Consortium for Drug-resistant Tuberculosis Diagnostics has completed its study. It is sponsored by the …
-
CLINICAL_TRIALS trial_result · 2014-04-23Clinical Trial Update: Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide [Phase 3]
A Phase 3 clinical trial is exploring optimization of multidrug-resistant tuberculosis treatment based on molecular drug susceptibility resu…
-
EMA guidance · 2014-03-21World TB Day – three new medicines recommended in last six months for patients with multidrug-resistant tuberculosis
EMA highlights three new medicines recommended in the last six months for patients with multidrug-resistant tuberculosis, signaling progress…
-
FDA approval · 2014-03-19FDA Approved: SIRTURO — Supplemental Application (Janssen Products, LP)
FDA approved a supplemental application for SIRTURO (bedaquiline fumarate) from Janssen Products, LP, resulting in changes to the drug’s lab…
-
CLINICAL_TRIALS trial_result · 2014-02-24Clinical Trial Update: Linezolid to Treat Extensively-Drug Resistant Tuberculosis [Phase 2]
A Phase 2 trial evaluating linezolid for extensively drug-resistant tuberculosis has completed, with results posted in 2014. The study encom…
-
EMA approval · 2013-12-20European Medicines Agency recommends approval of a new medicine for multidrug-resistant tuberculosis
EMA recommends approval of a new medicine for multidrug-resistant tuberculosis, marking a potential new treatment option for this challengin…
-
FDA approval · 2013-08-28FDA Approved: SIRTURO — Supplemental Application (Janssen Products, LP)
The FDA approved a supplemental application for SIRTURO (bedaquiline fumarate) submitted by Janssen Products, LP.
-
CLINICAL_TRIALS trial_result · 2013-07-10Clinical Trial Update: Metronidazole for Pulmonary Tuberculosis (South Korea) [Phase 2]
Phase 2 trial evaluating metronidazole for pulmonary tuberculosis, including multidrug-resistant TB. Results were posted in 2013.
-
CLINICAL_TRIALS trial_result · 2013-07-01Clinical Trial Update: Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients [Phase 4]
A Phase 4 drug interaction study assessed the combination of linezolid and clarithromycin in patients with multidrug-resistant tuberculosis …
-
CLINICAL_TRIALS trial_result · 2013-06-25Clinical Trial Update: TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB). [Phase 2]
Phase 2 clinical trial results assessing bedaquiline (TMC207) for safety, tolerability, and anti-mycobacterial activity in participants with…
-
CLINICAL_TRIALS trial_result · 2013-05-16Clinical Trial Update: To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB. [Phase 2]
Phase 2 trial evaluating the safety, tolerability, and efficacy of bedaquiline (TMC207) as part of an individualized MDR-TB treatment regime…
-
CLINICAL_TRIALS research · 2013-03-29Clinical Trial Update: Epidemiology of MDR-TB in Peru
An update on the epidemiology of multidrug-resistant tuberculosis in Peru from the NCT00676754 trial led by Harvard researchers.
-
FDA approval · 2012-12-28FDA Approved: SIRTURO — Original Application (Janssen Products, LP)
FDA approved SIRTURO (bedaquiline fumarate) from Janssen as the original application for the treatment of multidrug-resistant tuberculosis.
-
CLINICAL_TRIALS trial_result · 2012-11-27Clinical Trial Update: Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients [Phase 3]
A Phase 3 trial comparing levofloxacin and moxifloxacin in multidrug-resistant tuberculosis was terminated.
-
CLINICAL_TRIALS trial_result · 2011-11-07Clinical Trial Update: Dose Escalation Study of SQ109 in Healthy Adult Volunteers [Phase 1]
Phase 1 dose-escalation study of SQ109 in healthy adults has completed, assessing safety and tolerability for potential tuberculosis treatme…
-
CLINICAL_TRIALS trial_result · 2007-08-08Clinical Trial Update: High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis [Phase 2, Phase 3]
Phase 2/3 trial evaluating high-dose isoniazid as adjuvant therapy for multidrug-resistant tuberculosis has completed.